June 11-17 - TheStreet

A June 8 story,

Dueling Drugs May End Up With Dual Approval, misspelled the name of a


(GENZ:Nasdaq) drug. It is Fabrazyme, not Fabryzyme. (

corrected June 11


A table in a June 8 story,

False Hopes for Sky High Growth Linger in Tech Valuations, incorrectly listed


(XLNX:Nasdaq) trailing price-to-earnings ratio as 4.5. It is 42.5. The story also incorrectly stated that


(CSCO:Nasdaq) shares had fallen 84% since last March. They have actually fallen 75%. (

corrected June 11